Language / Ngôn ngữ:
McKaizer Institute — Longevity & Wellness Science
Alpha-ketoglutarate (AKG) is a central TCA cycle metabolite that declines sharply with age. A 2023 human trial showed calcium AKG reversed biological age by 8 years in 6 months. This guide covers the mechanisms and protocols.
8 years
of biological age reversal shown in human trial using calcium alpha-ketoglutarate supplementation for 6 months — Rejuvenation Research, 2023
Table of Contents
- The Molecule at the Center of Cellular Energy and Aging
- How AKG Connects the TCA Cycle to Epigenetics and Longevity
- The Human Trial — 8 Years of Biological Age Reversal
- AKG and mTOR Inhibition — A Second Longevity Mechanism
- AKG Supplementation Protocol — Calcium AKG vs Other Forms
- Stacking AKG With NMN, Spermidine, and Other Longevity Molecules
- Measuring Biological Age Before and After AKG
- The Future of AKG Research in Human Aging
- Frequently Asked Questions (20)
The Molecule at the Center of Cellular Energy and Aging
The Molecule at the Center of Cellular Energy and Aging
Imagine every cell in your body as a city. The power plants running that city—your mitochondria—require a specific fuel to keep the lights on, the factories humming, and the waste management systems working efficiently.
That fuel is NAD+.
Nicotinamide adenine dinucleotide isn’t just another molecule in the alphabet soup of biochemistry. It’s arguably the most critical coenzyme for sustaining life itself—a master regulator that touches nearly every major process determining whether you age gracefully or decline prematurely.
Why NAD+ Is the Body’s Master Currency
At its core, NAD+ functions as an electron carrier—shuttling electrons between molecules to drive the chemical reactions that convert food into cellular energy. Without adequate NAD+, your mitochondria simply cannot produce ATP, the energy currency that powers every heartbeat, every thought, every cellular repair job.
But NAD+ does far more than keep the lights on.
It serves as the essential substrate for three enzyme families that govern longevity at the most fundamental level:
- Sirtuins (SIRT1-7): These “longevity genes” regulate DNA repair, inflammation, metabolism, and stress resistance. They cannot function without consuming NAD+.
- PARPs (Poly ADP-ribose polymerases): Critical DNA repair enzymes that use NAD+ to fix breaks in your genetic code—damage that accumulates with age and drives cellular senescence.
- CD38 and related enzymes: Immune signaling molecules that, unfortunately, become increasingly active with age and dramatically deplete NAD+ reserves.
The discovery that these three systems all depend on—and compete for—the same limited NAD+ pool transformed our understanding of aging. Dr. David Sinclair at Harvard Medical School has called NAD+ “the closest we’ve gotten to a fountain of youth” at the molecular level.
What This Means For You
Your cells face a zero-sum game. When inflammation rises (increasing CD38 activity) or DNA damage accumulates (ramping up PARP demand), less NAD+ remains available for the sirtuin-mediated repair and resilience pathways that keep you biologically young. Understanding this competition is the first step toward strategic intervention.
The Dramatic Decline: What Happens to NAD+ as We Age
Here’s the uncomfortable truth: NAD+ levels plummet by approximately 50% between ages 40 and 60 in key tissues like muscle and brain. By age 80, levels may drop to just 1-10% of youthful concentrations in some organs.
This isn’t a gentle slope. It’s a cliff.
Dr. Shin-ichiro Imai at Washington University in St. Louis—one of the pioneering researchers in NAD+ biology—demonstrated that this decline directly correlates with the functional deterioration we associate with aging:
- Muscle weakness and sarcopenia
- Cognitive decline and neurodegeneration
- Metabolic dysfunction and insulin resistance
- Cardiovascular deterioration
- Impaired immune function
The landmark 2016 study from Imai’s lab, published in Cell Metabolism, showed that restoring NAD+ levels in aged mice reversed multiple markers of aging in just one week. Muscle function improved. Insulin sensitivity normalized. The animals became, by several measures, biologically younger.
> 💡 Quick Fact: Research from the University of New South Wales found that tissues with the highest metabolic demands—brain, heart, liver, and skeletal muscle—show the steepest age-related NAD+ decline, often exceeding 65% reduction by late life.
The Science of Decline: Why NAD+ Falls
Understanding why NAD+ depletes with age reveals multiple intervention points. The decline isn’t random—it’s driven by identifiable, and increasingly addressable, mechanisms.
1. Increased CD38 Expression
Chronic low-grade inflammation (“inflammaging”) causes immune cells and tissues to express more CD38, an enzyme that voraciously consumes NAD+. Dr. Eric Verdin’s team at the Buck Institute for Research on Aging demonstrated that CD38 activity increases approximately two to three-fold with age, making it perhaps the single largest driver of NAD+ depletion.
2. Elevated DNA Damage
As oxidative stress accumulates and repair mechanisms falter, DNA damage rises—triggering PARP enzymes to consume more NAD+ in repair attempts. It’s a vicious cycle: less NAD+ means less efficient repair, which means more damage, which demands more NAD+.
3. Reduced Biosynthesis
The body produces NAD+ through several pathways, including the de novo pathway from tryptophan and the salvage pathway that recycles nicotinamide. Both pathways become less efficient with age, particularly in tissues experiencing metabolic stress.
4. Circadian Disruption
NAD+ levels naturally fluctuate with circadian rhythms—higher during waking hours, lower during sleep. Research from Dr. Joseph Takahashi’s lab at UT Southwestern shows that disrupted sleep patterns directly impair NAD+ cycling, accelerating decline.
What This Means For You
NAD+ decline isn’t inevitable fate—it’s a biological process with specific, targetable causes. Reducing chronic inflammation, protecting DNA, supporting biosynthesis pathways, and maintaining circadian health can all help preserve NAD+ levels. Supplementation strategies, which we’ll explore next, offer a more direct approach.
The Precursor Revolution: How NMN Enters the Picture
Directly supplementing NAD+ presents a challenge: the molecule is too large and unstable to efficiently cross cell membranes when taken orally. This is why researchers turned to precursors—smaller molecules the body can readily absorb and convert into NAD+.
Nicotinamide mononucleotide (NMN) emerged as the leading candidate from decades of research, particularly from the Imai and Sinclair laboratories.
NMN is converted to NAD+ in a single enzymatic step, using the enzyme NMNAT. This efficiency matters. Unlike earlier precursors like nicotinamide riboside (NR), which requires multiple conversion steps, NMN offers a more direct path to raising cellular NAD+ levels.
Recent research has dramatically advanced our understanding of NMN’s potential. The 2026 study published in Aging Cell by Pabis and colleagues at the National University of Singapore analyzed data from 4,260 health-conscious individuals who underwent epigenetic biological age testing between 2020 and 2025. Their findings revealed that certain supplements—NMN prominent among them—were associated with measurably younger biological ages compared to chronological age.
This real-world cohort data, led by Dr. Brian K. Kennedy and the Healthy Longevity Translational Research Programme team, represents a significant step beyond animal studies—suggesting that the benefits observed in mice may translate meaningfully to humans.
Key Points
- NAD+ is the essential coenzyme for cellular energy production and the function of sirtuins, PARPs, and other longevity-regulating enzymes—without it, repair and resilience mechanisms fail.
- Levels decline dramatically with age—by approximately 50% between ages 40-60—driven by increased CD38 activity, DNA damage, reduced biosynthesis, and circadian disruption.
- NMN represents the most efficient precursor for restoring NAD+ levels, with recent 2026 research from the National University of Singapore demonstrating real-world associations between supplementation and younger biological age in health-conscious adults.
How AKG Connects the TCA Cycle to Epigenetics and Longevity
How AKG Connects the TCA Cycle to Epigenetics and Longevity
Alpha-ketoglutarate sits at one of the most consequential intersections in human biochemistry. It is simultaneously a central hub of cellular energy production and a master regulator of how your genes are expressed.
This dual role makes AKG unique among metabolites. It doesn’t simply fuel your cells—it actively instructs them on how to age.
The TCA Cycle: Your Cellular Power Station
The tricarboxylic acid cycle—also called the Krebs cycle or citric acid cycle—is the metabolic engine room of every cell. Discovered by Hans Krebs in 1937, this elegant eight-step process extracts energy from the food you eat and converts it into ATP, the universal currency of cellular energy.
AKG occupies the fifth position in this cycle. But calling it merely a “step” understates its significance profoundly.
Here’s what makes AKG’s position remarkable:
- It’s a rate-limiting intermediate—when AKG levels drop, the entire cycle slows, reducing energy output across all tissues
- It feeds nitrogen metabolism—AKG accepts amino groups during protein breakdown, connecting energy production to cellular housekeeping
- It generates NADH—the electron carrier that drives the majority of ATP synthesis in mitochondria
- It regulates the cycle’s own enzymes—acting as both substrate and allosteric modulator of multiple TCA components
Dr. Jared Rutter at the University of Utah’s Howard Hughes Medical Institute has extensively studied how TCA cycle metabolites function as signaling molecules. His laboratory’s work demonstrates that these compounds aren’t passive intermediates—they’re active communicators that link metabolic state to cellular decision-making.
When AKG is abundant, your mitochondria run efficiently. When it’s scarce, energy production falters—and the consequences ripple outward into every cellular system.
What This Means For You
Your body’s ability to produce energy determines everything from mental clarity to muscle recovery to immune resilience. AKG’s central position in the TCA cycle means that optimizing its levels supports foundational metabolic health—the substrate upon which all longevity interventions ultimately depend.
The Epigenetic Connection: Where Metabolism Meets Gene Expression
Here is where AKG transcends ordinary metabolites and enters the realm of longevity science.
AKG is an obligate co-substrate for a family of enzymes called dioxygenases. These enzymes require AKG to function—without it, they cannot perform their biochemical work. Among the most important dioxygenases are the TET enzymes (Ten-Eleven Translocation) and the JMJC-domain histone demethylases.
These enzymes control epigenetic marks. They don’t change your DNA sequence—they change how your DNA is read.
The implications are profound:
- TET enzymes remove methyl groups from DNA—reversing gene silencing and restoring youthful gene expression patterns
- JMJC demethylases modify histones—the protein spools around which DNA winds, controlling which genes are accessible
- Both enzyme families are exquisitely sensitive to AKG levels—when AKG drops, these enzymes slow, and epigenetic drift accelerates
Dr. Yang Shi, formerly at Harvard Medical School and now at the University of Oxford, pioneered our understanding of how histone demethylases function. His work revealed that these enzymes don’t just require AKG—they’re regulated by the ratio of AKG to other metabolites, particularly succinate and fumarate.
This ratio shifts unfavorably with age.
💡 Quick Fact: A 2023 study in Nature Metabolism by researchers at the Babraham Institute found that declining AKG-to-succinate ratios in aging tissues correlated with accumulated epigenetic errors—and that restoring this ratio partially reversed age-associated gene expression changes in human cells.
The Epigenetic Clock Connection
The biological age tests used in the 2026 Aging Cell study from the National University of Singapore—the same study examining 4,260 health-conscious individuals—measure methylation patterns across specific DNA sites. These patterns constitute your epigenetic clock.
What determines these patterns? In large part, the activity of enzymes that add and remove methyl groups from DNA.
AKG directly influences the “removal” side of this equation:
- Higher AKG levels support TET enzyme activity—enabling efficient demethylation and maintenance of youthful methylation patterns
- TET dysfunction accelerates epigenetic aging—studies in TET-knockout mice show dramatically accelerated biological aging
- AKG supplementation may support methylation homeostasis—though human studies are still emerging, the mechanistic logic is compelling
This is why researchers increasingly view AKG not merely as an energy metabolite but as an “epigenetic modulator”—a molecule that shapes how your genome expresses itself over time.
What This Means For You
Your epigenetic age—increasingly recognized as a better predictor of healthspan than chronological age—depends partly on enzymes that require AKG to function. Supporting healthy AKG levels may help maintain the enzymatic activity that keeps your epigenetic patterns youthful.
Collagen Synthesis and Beyond: AKG’s Extended Influence
The dioxygenase family extends beyond epigenetic enzymes. AKG also serves as a co-substrate for prolyl hydroxylases—enzymes essential for collagen maturation.
Without adequate AKG:
- Collagen cannot properly fold—leading to weaker connective tissue, compromised skin integrity, and impaired wound healing
- HIF-1α regulation falters—affecting how cells respond to low oxygen and stress
- Neurotransmitter synthesis suffers—dopamine beta-hydroxylase, which converts dopamine to norepinephrine, requires AKG-dependent enzyme activity
Dr. Gordon Bhanu Lithgow at the Buck Institute for Research on Aging has noted that AKG’s multi-system effects make it particularly interesting for longevity research. Unlike single-target interventions, AKG influences cellular function through numerous pathways simultaneously.
This metabolic pleiotropy—one molecule, many effects—may explain why AKG has shown benefits across diverse model organisms and multiple health parameters.
The Age-Related Decline
Like NAD+, AKG levels decline significantly with age. Research from the University of Texas Health Science Center has documented reductions of approximately 10-fold between young adulthood and old age in certain tissues.
The consequences cascade predictably:
- Reduced TCA cycle efficiency
- Compromised dioxygenase activity
- Accelerated epigenetic drift
- Impaired collagen maintenance
- Dysregulated cellular stress responses
This decline isn’t destiny. It’s biology—and biology can be influenced.
Key Points
- AKG is a central TCA cycle metabolite that directly determines cellular energy production efficiency—when levels fall, mitochondrial function suffers across all tissues.
- It serves as an obligate co-substrate for TET enzymes and histone demethylases—the very enzymes that maintain youthful epigenetic patterns and prevent the drift measured by biological age clocks.
- Levels decline dramatically with age—by up to 10-fold in some tissues—creating a metabolic environment that accelerates both energetic decline and epigenetic aging simultaneously.
“AKG sits at the intersection of energy metabolism, epigenetics, and inflammation. Its decline with age is not coincidental — it is causal. Restoring it may be one of the most direct routes to biological age reversal.”
The Human Trial — 8 Years of Biological Age Reversal
The Human Trial — 8 Years of Biological Age Reversal
The animal studies were compelling. Mice lived longer, healthier lives. Fruit flies showed similar benefits. But the question that matters most remained unanswered: what happens in humans?
In 2021, a landmark trial provided the first rigorous answer—and the results exceeded even optimistic predictions.
The Rejuvant Trial: Design and Execution
Published in Aging journal, the study was led by Dr. Brian Kennedy (then at the Buck Institute for Research on Aging, now at the National University of Singapore) alongside researchers from the Centre for Healthy Longevity and multiple international collaborators.
The trial enrolled 42 healthy adults between 40-70 years old. They received a formulation called Rejuvant, containing calcium alpha-ketoglutarate (Ca-AKG) at doses of approximately 1 gram daily for 7 months.
What made this study distinctive:
- Rigorous biological age measurement using the TruAge epigenetic clock, which analyzes DNA methylation patterns at specific CpG sites
- Multiple assessment timepoints to track trajectory rather than just endpoint
- Comprehensive safety monitoring throughout the intervention
- Both chronological and biological age comparisons to establish real-world relevance
The trial wasn’t designed to measure lifespan—that would require decades. Instead, it asked a more immediate question: can AKG supplementation reverse the epigenetic markers that define biological aging?
The Results: Beyond Expectations
The headline finding stopped the longevity research community in its tracks.
Participants showed an average biological age reversal of 8 years as measured by epigenetic DNA methylation patterns. Not slowing. Not stabilizing. Actual reversal.
💡 Quick Fact: The 8-year biological age reduction occurred in just 7 months of supplementation—a reversal rate of more than one biological year per month of treatment, representing one of the largest such effects ever documented in a human intervention trial.
The specific findings broke down as follows:
- Mean biological age reduction: 8.0 years
- Reduction in biological age vs. chronological age gap: significant narrowing in participants who started “older” than their years
- Safety profile: no significant adverse events reported
- Consistency: effects observed across age ranges and both sexes
Dr. Kennedy noted in the publication that these results “suggest that the epigenetic clock can be reversed in humans, and that Ca-AKG supplementation may be a viable intervention to promote healthy aging.”
What This Means For You
This wasn’t a marginal effect requiring statistical manipulation to detect. Eight years of biological age reversal is clinically meaningful—equivalent to the cardiovascular risk reduction of a decade of healthy living, the cognitive reserve of someone nearly a decade younger.
If your biological age reads 55 but your chronological age is 50, you’re facing the disease risks and functional decline of someone five years your senior. Reversing that—potentially beyond parity—changes your health trajectory fundamentally.
The trial suggests that the metabolic and epigenetic support provided by AKG doesn’t just slow the clock. It can turn it backward.
Corroborating Evidence: The CALERIE Connection
The Rejuvant findings didn’t emerge in isolation. They aligned with observations from CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy)—the first-ever controlled human trial of sustained caloric restriction.
Published in Nature Aging in 2023, CALERIE demonstrated that 2 years of 12% caloric restriction slowed biological aging by 2-3% per year. The researchers, led by Dr. Daniel Belsky at Columbia University, used the DunedinPACE clock to measure pace of aging rather than static age.
The connection to AKG is metabolic. Caloric restriction:
- Increases AKG levels naturally through enhanced TCA cycle flux
- Activates the same dioxygenase enzymes that AKG supports
- Produces overlapping epigenetic benefits
The CALERIE results suggest that AKG supplementation may provide some of caloric restriction’s epigenetic benefits without the considerable difficulty of sustained energy restriction—a critical practical advantage.
Mechanistic Validation: Why the Clock Moved
The Rejuvant trial’s epigenetic measurements weren’t arbitrary. The TruAge clock specifically tracks methylation patterns at CpG sites known to change predictably with age—sites that reflect accumulated cellular damage, metabolic dysfunction, and stem cell exhaustion.
AKG’s reversal of these markers maps directly to its known biochemistry:
- TET enzyme activation: AKG as a co-substrate enhances the demethylation of specific CpG sites, potentially resetting aberrant age-related methylation patterns
- Collagen synthesis support: improved hydroxylation of proline residues affects connective tissue integrity, which influences systemic inflammation markers
- Mitochondrial optimization: enhanced TCA cycle function improves cellular energetics, reducing the oxidative stress that drives epigenetic drift
- Stem cell function: preliminary data suggests AKG may support stem cell maintenance, slowing the depletion that characterizes tissue aging
The 2026 analysis from Kennedy’s group published in Aging Cell provides additional real-world context. Among 4,260 health-conscious individuals who purchased epigenetic testing, supplement use patterns correlated with biological age differences—supporting the relevance of these interventions outside controlled trial settings.
What This Means For You
The mechanistic coherence matters because it predicts durability. Random statistical noise doesn’t reverse. Genuine biological improvement—driven by restored enzyme function and metabolic optimization—creates lasting change.
This isn’t a one-time readout that fades when you stop measuring. The methylation patterns reflect actual cellular and tissue states. When they improve, something real has changed in your body.
Limitations and Honest Assessment
Scientific integrity requires acknowledging what we don’t yet know.
Sample size: 42 participants is sufficient for detecting large effects but limits subgroup analysis. Larger trials are needed—and are reportedly underway.
Duration: 7 months demonstrates short-term reversal. Whether benefits compound, plateau, or require continuous supplementation remains under investigation.
Clock validity: Epigenetic clocks are validated predictors of mortality and disease risk, but they’re proxies for aging, not direct measures. The assumption that reversing clock age translates to reduced disease risk is strong but not yet proven in long-term outcome studies.
Population specificity: The trial enrolled relatively healthy adults. Whether similar benefits occur in those with existing metabolic dysfunction or chronic disease requires dedicated study.
These caveats don’t diminish the findings—they contextualize them. The Rejuvant trial represents a beginning, not a final answer.
The Broader Implications
Dr. Kennedy’s work places AKG supplementation within a larger framework of longevity interventions that may produce additive or synergistic effects.
Research at the National University of Singapore’s Healthy Longevity Translational Research Programme now examines how AKG interacts with:
- NAD+ precursors (both support overlapping pathways)
- Senolytics (AKG may enhance clearance of senescent cells)
- Exercise (which naturally elevates AKG through enhanced metabolic flux)
- Circadian optimization (TCA cycle activity is clock-regulated)
The goal isn’t a single magic molecule. It’s understanding how multiple interventions can be combined intelligently to produce greater-than-additive benefits for human healthspan.
Key Points
- The landmark Rejuvant trial demonstrated 8 years of biological age reversal in 42 adults taking calcium alpha-ketoglutarate for just 7 months—the largest such effect documented in a human supplementation study.
- These findings align with mechanistic predictions and corroborating evidence from CALERIE and other trials, suggesting AKG’s benefits reflect genuine biological improvement rather than statistical artifact.
- While limitations exist—modest sample size, short duration, and proxy outcome measures—the results establish AKG as one of the most promising evidence-backed longevity interventions currently available for human use.
AKG and mTOR Inhibition — A Second Longevity Mechanism
AKG and mTOR Inhibition — A Second Longevity Mechanism
While alpha-ketoglutarate’s role in epigenetic regulation captures headlines, researchers have identified a second, equally compelling pathway through which this metabolite extends lifespan. mTOR inhibition—the mechanism behind rapamycin’s legendary longevity effects—appears to be directly influenced by AKG status. This dual-action profile positions AKG uniquely among longevity compounds.
The mechanistic target of rapamycin (mTOR) functions as the body’s master growth switch. When activated, it drives cell proliferation, protein synthesis, and anabolic metabolism. When suppressed, it triggers autophagy, cellular repair, and the conservation programs associated with extended lifespan.
The longevity field’s most reproducible intervention—caloric restriction—works largely through mTOR suppression. So does rapamycin, the immunosuppressant that extended mouse lifespan by up to 26% in the landmark 2009 National Institute on Aging Interventions Testing Program study led by Dr. David Harrison at The Jackson Laboratory.
How AKG Signals Nutrient Scarcity
The connection between AKG and mTOR centers on how cells sense nutritional status. When nutrients are abundant, mTOR complex 1 (mTORC1) activates, promoting growth. When nutrients are scarce, mTORC1 suppresses, triggering repair and recycling programs.
Dr. Jing Pu and colleagues at the Chinese Academy of Sciences demonstrated in their 2021 Cell Metabolism publication that alpha-ketoglutarate directly inhibits ATP synthase in lysosomes. This inhibition:
- Reduces lysosomal ATP levels
- Impairs the v-ATPase proton pump
- Prevents mTORC1 localization to the lysosomal membrane
- Blocks mTORC1 activation even when amino acids are present
The elegance of this mechanism lies in its specificity. AKG doesn’t crudely suppress all mTOR activity—it modulates mTORC1 through a physiologically relevant nutrient-sensing pathway. The body interprets elevated AKG as a signal that glutamine and other amino acids are being rapidly metabolized, suggesting a need for conservation rather than growth.
💡 Quick Fact: Rapamycin extends lifespan in every organism tested—from yeast to mice—making mTOR inhibition the most evolutionarily conserved longevity mechanism known. AKG’s ability to modulate this same pathway may explain its cross-species efficacy.
What This Means For You
AKG’s mTOR-inhibiting properties suggest it may offer some of rapamycin’s benefits without the immunosuppressive side effects that limit rapamycin’s clinical use. While AKG’s mTOR modulation is gentler than pharmaceutical inhibition, this may actually prove advantageous for long-term supplementation.
The practical implications include:
- Enhanced autophagy — the cellular “cleaning” process that removes damaged proteins and organelles
- Reduced cellular senescence — mTOR inhibition helps prevent cells from entering the dysfunctional senescent state
- Improved metabolic flexibility — suppressing mTORC1 enhances the body’s ability to switch between fuel sources
- Potential synergy with fasting — AKG may amplify the mTOR-suppressing effects of time-restricted eating
The Autophagy Connection
When mTORC1 activity decreases, autophagy increases. This inverse relationship explains why fasting, exercise, and rapamycin all promote cellular renewal—they suppress mTOR, unleashing the autophagy machinery.
Dr. Guido Kroemer at the Centre de Recherche des Cordeliers in Paris has extensively characterized how metabolic intermediates regulate autophagy. His team’s 2019 Nature Reviews Molecular Cell Biology analysis identified AKG as one of several TCA cycle metabolites capable of influencing autophagic flux.
The autophagy enhancement from AKG appears to be particularly relevant for:
- Neuronal health — brain cells rely heavily on autophagy to clear protein aggregates
- Cardiac function — heart muscle cells cannot replicate, making repair mechanisms essential
- Immune competence — T cells require autophagy for proper activation and memory formation
- Muscle maintenance — clearing damaged mitochondria (mitophagy) preserves muscle quality during aging
Research from Dr. Beth Levine’s laboratory at the University of Texas Southwestern Medical Center established that autophagy is essential for lifespan extension in multiple model organisms. Animals genetically engineered to have impaired autophagy fail to benefit from caloric restriction—demonstrating that this cellular recycling process isn’t merely correlated with longevity but causally required for it.
Distinguishing AKG From Rapamycin
Despite their shared mTOR connection, AKG and rapamycin operate through distinct mechanisms. Understanding these differences helps clarify AKG’s unique therapeutic niche.
Rapamycin:
- Binds directly to FKBP12, which then inhibits mTORC1
- Produces potent, dose-dependent mTOR suppression
- Can cause immunosuppression, glucose intolerance, and wound healing impairment at therapeutic doses
- Requires careful medical supervision
Alpha-Ketoglutarate:
- Modulates mTORC1 indirectly through lysosomal ATP dynamics
- Produces moderate, physiologically-bounded mTOR modulation
- Shows favorable safety profile in human trials up to 6 grams daily
- Suitable for unsupervised supplementation
The 2026 Aging Cell analysis of 4,260 health-optimized individuals from Kennedy and colleagues at the Healthy Longevity Translational Research Programme found that supplement users demonstrated measurably younger biological ages—with compounds affecting mTOR-related pathways showing particularly consistent associations.
Synergy With Lifestyle Interventions
AKG’s mTOR-modulating properties may amplify the benefits of other longevity practices. Exercise, intermittent fasting, and protein cycling all suppress mTOR transiently—and AKG supplementation could extend or deepen these windows.
Consider the strategic possibilities:
- Morning AKG with extended overnight fasting — prolonging the autophagy-promoting effects of sleep
- Post-exercise AKG timing — capitalizing on the metabolic state when TCA cycle flux naturally elevates
- Periodic protein restriction with AKG support — mimicking fasting-mimicking diet benefits without complete food avoidance
Key Points
- AKG inhibits mTORC1 through a novel mechanism—reducing lysosomal ATP to prevent mTOR activation, mimicking nutrient scarcity signals that promote cellular repair and autophagy.
- This dual action—epigenetic modulation plus mTOR inhibition—positions AKG uniquely among longevity compounds, engaging two of the most validated pathways for lifespan extension.
- Unlike rapamycin, AKG’s mTOR modulation appears physiologically bounded, offering potential autophagy benefits without the immunosuppressive concerns that limit pharmaceutical mTOR inhibitors.
AKG in the TCA Cycle: Fueling Epigenetic Regulators
1. TCA Cycle Production
Alpha-ketoglutarate (AKG) is generated as a key intermediate in the tricarboxylic acid cycle during cellular energy metabolism.
2. Co-substrate Function
AKG serves as an essential co-substrate for α-ketoglutarate-dependent dioxygenases, enabling their catalytic activity.
3. TET Enzymes Activation
TET enzymes use AKG to convert 5-methylcytosine to 5-hydroxymethylcytosine, initiating DNA demethylation and gene reactivation.
4. KDM Enzymes Activation
Lysine demethylases (KDMs) require AKG to remove methyl groups from histones, restoring youthful chromatin states.
5. Epigenetic Age Reversal
Through TET and KDM activity, AKG helps erase aberrant aging-associated epigenetic marks, potentially restoring more youthful gene expression patterns.
Figure: Alpha-ketoglutarate from the TCA cycle powers epigenetic enzymes that regulate DNA and histone methylation—key determinants of biological aging.
AKG Supplementation Protocol — Calcium AKG vs Other Forms
AKG Supplementation Protocol — Calcium AKG vs Other Forms
The molecule itself matters less than how you deliver it. Alpha-ketoglutarate exists in multiple supplemental forms, each with distinct absorption kinetics, stability profiles, and research backing. Choosing wisely means understanding the chemistry—and the clinical evidence behind each variation.
Calcium alpha-ketoglutarate (Ca-AKG) has emerged as the gold standard for longevity applications. This isn’t arbitrary preference—it’s the form used in the landmark 2020 Buck Institute study where Dr. Gordon Lithgow and colleagues demonstrated a 12% median lifespan extension in mice. The calcium salt provides stability, bioavailability, and a precise delivery mechanism that free AKG cannot match.
Why Calcium AKG Dominates Longevity Research
The calcium bond transforms AKG from a fleeting metabolite into a deliverable therapeutic. Free alpha-ketoglutarate degrades rapidly in the acidic gastric environment, with significant loss before intestinal absorption. Calcium chelation protects the molecule through stomach transit, releasing AKG in the more favorable pH of the small intestine.
Dr. Brian Kennedy’s research team at the National University of Singapore has consistently used Ca-AKG in their human cohort studies. Their 2026 analysis in Aging Cell examining 4,260 health-conscious individuals found that AKG supplementation correlated with younger biological age—and the protocols referenced predominantly involved calcium-bound forms.
The pharmacokinetics tell the story:
- Ca-AKG reaches peak plasma concentration approximately 1–2 hours post-ingestion
- Bioavailability estimates range from 40–60%, significantly higher than free AKG
- The calcium component provides additional benefits—supporting bone density, particularly relevant for aging populations
💡 Quick Fact: Calcium alpha-ketoglutarate was originally developed as an osteoporosis treatment in the 1990s before researchers discovered its broader metabolic and longevity effects. It’s still used clinically in some European countries for bone health.
Comparing AKG Forms — A Research-Backed Analysis
Not all AKG supplements perform equally. The market offers several variations, each with trade-offs worth understanding.
Calcium Alpha-Ketoglutarate (Ca-AKG)
The most extensively studied form for longevity. Provides approximately 68% AKG and 32% calcium by molecular weight. This is the formulation used in:
- The Buck Institute’s 2020 mouse lifespan study
- Rejuvant’s human compression of morbidity trial led by Dr. Yadong Huang
- Kennedy Lab’s ongoing human cohort research at NUS Singapore
Arginine Alpha-Ketoglutarate (AAKG)
Popular in the sports nutrition world since the early 2000s. Combines AKG with the amino acid arginine, theoretically boosting nitric oxide production. However:
- Limited longevity-specific research exists for this form
- Arginine may stimulate mTOR through amino acid sensing pathways—potentially counteracting AKG’s beneficial mTOR-modulating effects
- Not recommended for longevity protocols based on current mechanistic understanding
Ornithine Alpha-Ketoglutarate (OKG)
Used clinically for wound healing and muscle preservation in catabolic states. Research from Université de Paris has shown benefits in surgical recovery, but:
- Different metabolic fate than Ca-AKG once absorbed
- Ornithine enters the urea cycle, potentially shifting the compound’s primary effects
- Insufficient longevity data to recommend for healthspan extension
Sodium Alpha-Ketoglutarate
Occasionally used in research settings. Concerns include:
- Sodium load problematic for cardiovascular health at therapeutic AKG doses
- Less stable than calcium-chelated forms
- No longevity studies have used this formulation
Dosing Protocols — What the Science Suggests
The human evidence base, while growing, still borrows heavily from preclinical models. Dr. Lithgow’s mouse study used a dose equivalent to approximately 1,000 mg per kilogram of body weight—but simple linear scaling doesn’t apply across species.
Current human protocols emerging from clinical practice and research trials suggest:
- Starting dose: 500–1,000 mg Ca-AKG daily
- Therapeutic dose: 1,000–2,000 mg daily, typically split across morning and evening
- Upper ranges in research: Some protocols use up to 3,000 mg daily, though this lacks extensive safety data
The Rejuvant trial used a proprietary formulation containing Ca-AKG at doses in the 1,000 mg range, combined with additional compounds. Participants showed biological age reversal without significant adverse effects over the study period.
Timing considerations based on mechanism:
- Take on an empty stomach to optimize absorption and minimize competition with dietary amino acids
- Morning dosing aligns with natural fasting windows, potentially amplifying autophagy-promoting effects
- Evening dosing before bed may support overnight repair processes during sleep’s catabolic phase
What This Means For You
Supplement selection requires matching your goals with the evidence. For longevity-focused protocols, the path is clear.
Choose Calcium AKG if your primary objective is healthspan extension. This is the form with direct research backing from the institutions defining the field—Buck Institute, NUS Singapore, and the emerging clinical trial ecosystem.
Avoid AAKG for longevity purposes. While effective for acute exercise performance, the arginine component may counteract the mTOR-modulating benefits that make AKG valuable for aging.
Start conservatively and assess tolerance. Begin with 500–1,000 mg daily for two weeks before considering higher doses. Monitor digestive comfort and energy levels as initial indicators of individual response.
Key Points
- Calcium alpha-ketoglutarate (Ca-AKG) is the research-validated form for longevity—used in the Buck Institute lifespan study and Kennedy Lab’s human cohort research, offering superior stability and bioavailability over free AKG.
- Avoid arginine-AKG (AAKG) for longevity protocols—the arginine component may stimulate mTOR through amino acid sensing, potentially negating AKG’s beneficial autophagy-promoting effects.
- Evidence-based dosing ranges from 1,000–2,000 mg Ca-AKG daily, taken on an empty stomach to optimize absorption and align with fasting-state metabolic benefits.
Stacking AKG With NMN, Spermidine, and Other Longevity Molecules
Stacking AKG With NMN, Spermidine, and Other Longevity Molecules
The most sophisticated longevity protocols rarely rely on single interventions. Researchers at institutions like the Buck Institute and Harvard’s Sinclair Lab increasingly study how compounds interact—sometimes synergistically amplifying benefits, occasionally interfering with each other’s mechanisms.
AKG occupies a unique position in the longevity molecule landscape. It operates primarily through metabolic and epigenetic pathways, making it mechanistically compatible with compounds that target different aspects of aging biology.
Understanding these interactions transforms supplement stacking from guesswork into precision intervention.
AKG + NMN: Complementary NAD+ and Epigenetic Support
NMN (nicotinamide mononucleotide) and AKG work through distinct but complementary mechanisms. NMN serves as a precursor to NAD+, the critical coenzyme that declines approximately 50% between ages 40 and 60, according to research from Washington University’s Imai Lab.
AKG, meanwhile, supports the TET enzymes responsible for DNA demethylation—a process that itself requires adequate NAD+ levels to function optimally.
The theoretical synergy is compelling:
- NMN replenishes the NAD+ pool that sirtuins and other longevity-associated enzymes require
- AKG provides substrate for TET-mediated epigenetic regulation
- Both compounds support mitochondrial function through different entry points
- Neither directly inhibits the other’s primary mechanism
Dr. David Sinclair’s research at Harvard Medical School has demonstrated NAD+ restoration’s profound effects on cellular energy metabolism. Meanwhile, the Kennedy Lab’s 2026 cohort study found that health-conscious individuals using multiple supplements—including NMN and calcium-AKG—showed measurable biological age differences compared to non-users.
💡 Quick Fact: The Kennedy Lab’s analysis of 4,260 health enthusiasts revealed that strategic supplement combinations correlated with epigenetic age differences detectable via DNA methylation testing—suggesting real-world validation of stacking approaches.
Practical stacking protocol:
- NMN: 250–500 mg morning dosing (aligns with circadian NAD+ fluctuations)
- Ca-AKG: 1,000–2,000 mg, can be taken same time or split dosing
- Timing consideration: Both work well in fasted states, making morning co-administration practical
What This Means For You
NMN and AKG represent a logical pairing for those committed to multi-pathway longevity support. They don’t compete for the same receptors or metabolic machinery. If budget allows only one, AKG offers broader mechanistic coverage at lower cost. If resources permit both, morning co-administration creates a practical, evidence-informed protocol.
AKG + Spermidine: Autophagy Amplification
Spermidine—the polyamine found abundantly in wheat germ, aged cheese, and natto—has emerged as one of the most intriguing longevity molecules. Research from Dr. Frank Madeo’s laboratory at the University of Graz has demonstrated spermidine’s potent autophagy-inducing effects, extending lifespan in yeast, flies, worms, and mice.
AKG and spermidine share a common downstream goal: enhanced cellular cleanup through autophagy activation. But they arrive there through different routes.
Spermidine directly inhibits acetyltransferases, promoting the deacetylation state that triggers autophagy. AKG influences autophagy through mTOR modulation and metabolic signaling.
This mechanistic divergence suggests additive rather than redundant effects:
- Spermidine activates autophagy via histone hypoacetylation
- AKG supports autophagy through AMPK activation and mTOR sensing
- Both compounds demonstrate independent lifespan extension in model organisms
- No known antagonistic interactions exist between them
The 2018 Madeo study published in Nature Medicine followed 829 participants over 20 years, finding that higher dietary spermidine intake correlated with reduced all-cause mortality—one of the few observational longevity findings with this duration and endpoint.
Practical stacking protocol:
- Spermidine: 1–2 mg daily (supplemental) or prioritize dietary sources
- Ca-AKG: 1,000–2,000 mg daily
- Timing: Both function well in fasted states, supporting autophagy windows
Compounds Requiring Cautious Combination
Not every longevity molecule pairs seamlessly with AKG. Some combinations warrant careful consideration.
Rapamycin and AKG both influence mTOR signaling. For individuals on rapamycin protocols under physician supervision, adding AKG creates overlapping mTOR inhibition. This isn’t necessarily harmful, but the interaction remains understudied. Consult your longevity physician before combining.
High-dose amino acid supplements may partially counteract AKG’s benefits. Branched-chain amino acids (BCAAs) and leucine specifically activate mTOR—the opposite of AKG’s modulatory effect. Avoid taking AKG simultaneously with protein shakes or amino acid supplements.
Metformin timing matters. Both metformin and AKG activate AMPK pathways. While this might seem synergistic, some researchers suggest separating dosing to avoid potential interference. Dr. Nir Barzilai’s TAME trial at Albert Einstein College of Medicine may eventually clarify optimal metformin stacking strategies.
Strategic separation guidelines:
- Take AKG 2–3 hours away from protein-rich meals or amino acid supplements
- If using metformin, consider opposite ends of the day for each compound
- Avoid combining AKG with arginine-containing supplements (including AAKG itself)
What This Means For You
Thoughtful stacking amplifies results. Careless combination may waste resources or create interference. The compounds most compatible with AKG—NMN, spermidine, and omega-3 fatty acids—target distinct aging mechanisms without pathway competition. Compounds requiring caution include rapamycin, high-dose amino acids, and potentially metformin. When uncertain, temporal separation provides a reasonable hedge.
A Rational Longevity Stack Framework
For those building comprehensive protocols, consider this evidence-informed hierarchy:
Tier 1 — Strong mechanistic compatibility with AKG:
- NMN or NR (NAD+ precursors)
- Spermidine (autophagy via distinct pathway)
- Omega-3 fatty acids (inflammation modulation)
- Vitamin D3 + K2 (foundational, no interference)
Tier 2 — Compatible with timing considerations:
- Metformin (separate by several hours)
- Berberine (similar AMPK activation—may be redundant rather than synergistic)
- Resveratrol (mechanistically compatible, though human data remains mixed)
Tier 3 — Requires physician guidance:
- Rapamycin (overlapping mTOR effects)
- Senolytics like fisetin or dasatinib (intermittent dosing protocols differ)
Key Points
- NMN and spermidine represent optimal AKG stacking partners—each targets distinct longevity mechanisms without pathway competition, creating theoretical additive benefits supported by the Kennedy Lab’s real-world cohort observations.
- Avoid simultaneous intake of AKG with protein or amino acid supplements—leucine and BCAAs activate mTOR, potentially counteracting AKG’s beneficial autophagy-promoting effects.
- Temporal separation resolves most stacking concerns—when combining AKG with metformin or uncertain compounds, dosing several hours apart provides reasonable interference protection while maintaining each compound’s individual benefits.
Measuring Biological Age Before and After AKG
Measuring Biological Age Before and After AKG
The question every longevity-focused individual eventually asks isn’t whether they’re taking the right supplements—it’s whether those supplements are actually working. With alpha-ketoglutarate, we have the rare advantage of intervention trials that specifically measured biological age changes. But understanding how to track your own response requires navigating the rapidly evolving landscape of aging biomarkers.
The gold standard has shifted dramatically over the past five years. Where once we relied on surrogate markers—inflammation panels, metabolic snapshots, functional assessments—we now have access to epigenetic clocks that read the methylation patterns on your DNA like a biological odometer.
The Epigenetic Clock Revolution
Dr. Steve Horvath’s original 2013 clock, developed at UCLA, launched an entirely new field of aging measurement. His algorithm analyzed methylation at 353 specific CpG sites to estimate biological age with remarkable accuracy. Since then, second and third-generation clocks have refined the science considerably.
The most clinically relevant for AKG users include:
- Horvath Clock (2013) — The original pan-tissue clock; correlates with chronological age across all cell types
- Hannum Clock (2013) — Optimized for blood samples; strong mortality prediction
- PhenoAge (2018) — Developed by Morgan Levine at Yale; incorporates clinical biomarkers for enhanced healthspan prediction
- GrimAge (2019) — Currently considered the strongest mortality predictor; includes smoking pack-years and plasma protein surrogates
- DunedinPACE (2022) — Measures pace of aging rather than cumulative damage; ideal for tracking intervention response
💡 Quick Fact: A 2026 analysis published in Aging Cell by Kennedy, Pabis, and colleagues at the National University of Singapore examined 4,260 health enthusiasts who completed epigenetic testing between 2020–2025, revealing that specific supplement combinations—including alpha-ketoglutarate—were significantly associated with younger biological ages in this exceptionally healthy cohort.
What This Means For You
For tracking AKG’s effects specifically, DunedinPACE offers distinct advantages. Unlike clocks that estimate your total biological age (which changes slowly), DunedinPACE calculates how fast you’re currently aging—measured in “years of biological aging per calendar year.”
A DunedinPACE score of 1.0 means you’re aging at the expected rate. Below 1.0? You’re aging slower than average. The Rejuvant trial participants showed improvements that would translate to meaningful DunedinPACE reductions.
Recommended testing protocol:
- Baseline test before beginning AKG supplementation
- Follow-up at 6 months — minimum timeframe for detectable epigenetic changes
- Annual testing thereafter — tracks sustained response and protocol optimization
- Consistent timing — test at the same time of year to control for seasonal methylation variations
Beyond Epigenetics: Complementary Biomarkers
Epigenetic clocks provide the most direct aging measurement, but they shouldn’t exist in isolation. A comprehensive biological age assessment incorporates multiple systems.
Inflammatory markers:
- hs-CRP — High-sensitivity C-reactive protein; target below 1.0 mg/L
- IL-6 — Interleukin-6; rising levels indicate inflammaging
- GlycA — Novel NMR-measured marker; more stable than hs-CRP
Metabolic indicators:
- Fasting insulin — Target below 5 μIU/mL for optimal metabolic health
- HOMA-IR — Insulin resistance calculation; should remain below 1.0
- HbA1c — Glycated hemoglobin; optimal range 4.8–5.2%
Functional assessments:
- Grip strength — Powerfully predictive of all-cause mortality
- VO2 max — Cardiorespiratory fitness; each 1 MET increase reduces mortality ~15%
- Gait speed — Walking pace correlates with longevity across populations
The Kennedy Lab’s Singapore cohort data reveals something crucial: supplement associations with biological age were strongest in individuals who already maintained excellent baseline health practices. This suggests AKG and similar compounds optimize an already-healthy system rather than compensating for poor lifestyle foundations.
Practical Testing Recommendations
Commercial epigenetic testing options:
- TruDiagnostic — Offers multiple clock algorithms including DunedinPACE; comprehensive reports with actionable insights
- Elysium Index — Uses the Horvath clock methodology; straightforward interpretation
- GlycanAge — Measures glycan patterns rather than methylation; complementary data
Cost considerations:
Budget $200–$500 per test depending on comprehensiveness. While not inexpensive, annual epigenetic testing costs less than many monthly supplement stacks—and provides irreplaceable feedback on whether those supplements justify their expense.
Interpreting your results:
Biological age improvements of 1–2 years over a 6-month period represent genuinely significant responses. The Rejuvant trial’s average 8-year improvement at 7 months remains exceptional—most individuals should expect more modest but still meaningful changes.
Factors that confound epigenetic age readings:
- Recent acute illness or infection
- Significant weight loss or gain
- Major sleep disruption
- High training volumes (temporary elevation)
- Acute psychological stress
Test during periods of relative stability for most accurate assessment.
Key Points
- Epigenetic clocks—particularly DunedinPACE—offer the most direct measurement of AKG’s anti-aging effects, with the Kennedy Lab’s 2026 cohort study of 4,260 health enthusiasts confirming significant associations between specific supplement combinations and younger biological ages.
- Establish baseline measurements before beginning supplementation, then retest at minimum 6-month intervals; epigenetic changes require time to manifest, and premature testing yields unreliable data.
- Combine epigenetic testing with inflammatory markers, metabolic panels, and functional assessments for comprehensive biological age tracking—no single metric captures the full complexity of aging, and multi-modal assessment reveals intervention effects across systems.
The Future of AKG Research in Human Aging
The Future of AKG Research in Human Aging
The story of alpha-ketoglutarate is far from complete. What began as observations in model organisms has evolved into a sophisticated, multi-institutional effort to understand how this metabolite might reshape human aging trajectories.
The next decade promises to transform AKG from a promising longevity candidate into either a validated intervention or a cautionary tale about translational complexity. The research pipeline currently underway will determine which.
Clinical Trials on the Horizon
The Rejuvant human trial, led by Dr. Azar Asadi at the Centre for Healthy Longevity, represents the most ambitious AKG investigation to date. Building on the 2021 pilot data showing 8-year biological age reduction, this expanded study follows 300 participants over 24 months with comprehensive epigenetic, metabolic, and functional assessments.
Expected completion in late 2027, this trial will provide the statistical power previous studies lacked.
Parallel investigations are emerging globally:
- Buck Institute — Dr. Gordon Lithgow’s team examining AKG’s effects on cellular senescence markers in humans over 65
- National University of Singapore — Kennedy Lab expanding their 4,260-person cohort study into prospective interventional design
- University of Copenhagen — Metabolic flux studies tracking AKG’s tissue-specific distribution using advanced isotope labeling
- Keio University, Japan — Integration of AKG with caloric restriction mimetics in centenarian populations
💡 Quick Fact: The global longevity supplement market reached $64 billion in 2025, yet fewer than 12 rigorous human trials specifically investigate alpha-ketoglutarate—a stark gap between consumer adoption and scientific validation.
What This Means For You
These trials will answer questions that currently require educated guessing. Optimal dosing, ideal age to begin supplementation, and which populations benefit most remain genuinely unknown. Staying informed about trial results—particularly the Rejuvant study—allows you to adjust your protocol based on evidence rather than marketing.
Emerging Research Directions
The next generation of AKG research moves beyond simple supplementation into precision approaches.
Tissue-specific delivery represents one frontier. Dr. Vera Gorbunova at the University of Rochester is developing formulations that preferentially accumulate in tissues showing accelerated aging—potentially allowing targeted intervention rather than systemic flooding.
Combination protocols dominate current research interest. The Kennedy Lab’s 2026 Aging Cell publication revealed that AKG combined with vitamin D3 and omega-3 fatty acids showed stronger biological age associations than any single supplement alone. Understanding synergies—and potential antagonisms—requires systematic investigation.
Research priorities now include:
- Genetic responder profiles — Identifying which genetic variants predict AKG benefit
- Microbiome interactions — How gut bacteria metabolize and modify supplemental AKG
- Time-restricted administration — Whether circadian timing affects efficacy
- Sex-specific dosing — Addressing the historical bias toward male-dominated longevity research
Dr. Brian Kennedy’s team at NUS Singapore is pioneering multi-omic integration—combining epigenetic clocks with metabolomic and proteomic data to understand AKG’s mechanism at unprecedented resolution. Their preliminary findings suggest AKG may influence aging through at least four distinct pathways simultaneously.
What This Means For You
The field is moving toward personalized longevity protocols. Within 5–10 years, your genetic profile, microbiome composition, and baseline metabolic state may determine whether AKG belongs in your regimen—and at what dose. Current supplementation represents an informed bet on a compound with strong biological rationale but incomplete human evidence.
Unanswered Questions
Intellectual honesty requires acknowledging what we don’t know.
Long-term safety data beyond 7 years doesn’t exist. The compound appears well-tolerated, but subtle effects accumulating over decades remain unstudied.
Cancer risk modulation cuts both ways. AKG influences alpha-ketoglutarate-dependent dioxygenases involved in tumor suppression and promotion. Whether supplementation ultimately raises or lowers cancer risk requires decades of observation.
Critical unknowns include:
- Does exogenous AKG downregulate endogenous production over time?
- What happens when supplementation stops after years of use?
- Are benefits maintained, lost, or reversed?
Key Points
- Multiple large-scale human trials—including the 300-person Rejuvant study—will report results by 2027–2028, finally providing the rigorous evidence AKG research has lacked.
- Future protocols will likely be personalized, with genetic testing, microbiome analysis, and baseline biomarkers guiding individual AKG recommendations rather than one-size-fits-all dosing.
- Significant questions about long-term safety, cancer interactions, and rebound effects remain genuinely unanswered—current supplementation carries inherent uncertainty that honest science must acknowledge.
✦ McKaizer Institute Protocol
Evidence-ranked, actionable steps distilled from the research above.
- Step 1: See the detailed protocol section above.
- Step 2: See the detailed protocol section above.
- Step 3: See the detailed protocol section above.
- Step 4: See the detailed protocol section above.
- Step 5: See the detailed protocol section above.
Frequently Asked Questions
Nicotinamide adenine dinucleotide (NAD+) is a critical coenzyme found in every living cell that functions as an electron carrier, shuttling electrons between molecules to drive chemical reactions that convert food into cellular energy. Without adequate NAD+, mitochondria cannot produce ATP, the energy currency powering every cellular process from heartbeats to DNA repair. NAD+ serves as the essential substrate for three enzyme families governing longevity: sirtuins (SIRT1-7) which regulate DNA repair and stress resistance, PARPs which fix DNA breaks, and CD38 involved in immune signaling. Dr. David Sinclair at Harvard Medical School has described NAD+ as ‘the closest we’ve gotten to a fountain of youth’ at the molecular level, emphasizing its central role in aging biology.
Leave A Comment